Leukemia Immune Escape and HLA Loss of Heterozygosity: Understanding Clinical Implications for Allogeneic HCT-June 9, 2026
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP, São Paulo and CHC/UFPR in Curitiba, Brazil, examines how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.




